Currently out of the existing stock ratings of Travis Steed, 20 are a HOLD (25.32%), 53 are a BUY (67.09%), 6 are a SELL (7.59%).

Travis Steed

Work Performance Price Targets & Ratings Chart

Analyst Travis Steed, currently employed at BARCLAYS, carries an average stock price target met ratio of 52.03% that have a potential upside of 13.9% achieved within 131 days.

Travis Steed’s has documented 160 price targets and ratings displayed on 23 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on BDX, Becton Dickinson and Company at 14-Feb-2025.

Wall Street Analyst Travis Steed

Analyst best performing recommendations are on TNDM (TANDEM DIABETES CARE).
The best stock recommendation documented was for TNDM (TANDEM DIABETES CARE) at 8/24/2018. The price target of $45 was fulfilled within 7 days with a profit of $6.63 (17.28%) receiving and performance score of 24.68.

Average potential price target upside

of $36.26 (13.83%) on PODD (INSULET).
of $33.99 (12.1%) on ISRG (INTUITIVE SURGICAL).
of $31.89 (14.91%) on SYK (STRYKER).

ABT Abbott Laboratories AXNX Axonics Modulation Technologies DXCM DexCom INMD InMode Ltd ZBH Zimmer Biomet Holdings BAX Baxter International BDX Becton Dickinson and Company BSX Boston Scientific Corp EW Edwards Lifesciences Corp ISRG Intuitive Surgical MDT Medtronic PLC PODD Insulet SYK Stryker TNDM Tandem Diabetes Care CNMD CONMED LUNG Pulmonx Corp SWAV Shockwave Medical WMGI Wright Medical Group N.V INSP Inspire Medical Systems NARI Inari Medical SILK Silk Road Medical AXGN Axogen OM Outset Medical

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Matt Miksic (BARCLAYS)